Melkersson-Rosenthal Syndrome
Melkersson-Rosenthal syndrome (MRS) is a rare neuromucocutaneous disorder diagnosed clinically when at least 2 of the classic triad are present: recurrent orofacial edema (most common), facial nerve palsy, and fissured tongue (lingua plicata), with diagnosis confirmed by noncaseating granulomas on biopsy.
Clinical Features and Diagnostic Criteria
The complete triad appears in only 8-13% of cases 1, 2. Oligosymptomatic and monosymptomatic forms are far more common, making diagnosis challenging and often delayed by years 2, 3.
Key Clinical Manifestations
- Orofacial edema: Painless, recurrent, non-pitting swelling affecting lips (most commonly upper lip), cheeks, or periorbital regions. This is the most frequent presenting sign 1, 4, 5
- Facial nerve palsy: Unilateral or partial lower motor neuron facial paralysis, occurring in approximately 19% of cases 2
- Fissured tongue (lingua plicata): Present in 34-47% of cases 4, 2
Rarer Presentations to Recognize
Beyond the classic triad, watch for granulomatous blepharitis, gingivitis, and palatitis 4. The median time from first symptoms to diagnosis is 4 years (range 1-35 years), reflecting the diagnostic difficulty 2.
Diagnostic Workup
Perform a skin or mucosal biopsy of affected tissue to confirm noncaseating granulomas 2. This histopathological finding is essential for diagnosis, though clinical presentation drives initial suspicion 1, 5.
Key history elements include:
- Pattern of recurrent episodes over months to years
- Previous facial palsies (may have occurred decades earlier) 3
- Triggers: hot water, stress, infection, dental procedures 1
Important Comorbidities to Screen For
- Crohn's disease (5-8% of cases) 4, 2
- Sarcoidosis (documented overlap exists) 6
- Periodontal disease (14% of cases) 2
- Allergic conditions (14% of cases) 2
Do not test for C1q or C4 levels—these are consistently normal in MRS and will not aid diagnosis 2.
Management Approach
First-Line Treatment
For acute orofacial edema, use intralesional triamcinolone acetonide or betamethasone as first-line therapy 5. This provides targeted treatment with fewer systemic effects.
For systemic involvement or severe cases, initiate oral corticosteroids 5, 2, 6. This remains the mainstay of treatment for acute attacks.
Second-Line and Alternative Therapies
When corticosteroids fail or are contraindicated, consider in sequence:
- Oral doxycycline (can be combined with intralesional betamethasone) 5
- Metronidazole 2
- Dapsone 4, 2
- Methotrexate 4, 2
- Thalidomide 4, 2
For steroid-refractory cases, clofazimine (an anti-leprosy drug) represents an effective alternative 6. This is particularly relevant when immunosuppressants like leflunomide and tacrolimus have failed.
Important Treatment Caveats
Treatment responses are highly variable and inconsistent across patients 2. Many patients require no treatment at all—when intervention is necessary, it is typically for cosmetically or functionally significant edema 1.
Patient Education and Follow-Up
Educate patients about the benign, chronic-relapsing nature of the condition 1. Provide dietary recommendations to avoid potential triggers and schedule regular follow-up examinations to monitor for recurrences 1.
The dentist plays a crucial diagnostic role since the most significant changes occur in the orofacial region 1. Maintain a high index of suspicion in patients presenting with recurrent lip swelling or unexplained facial palsy.
Surgical Considerations
Surgery may be considered for persistent, disfiguring edema unresponsive to medical therapy, though this is rarely necessary 4.
Prognosis
MRS is a chronic condition with unpredictable recurrences. The syndrome can present across the entire lifespan (ages 8-79 years documented), with mean presentation around 35-39 years 4, 2. Several years of observation may be required before the full diagnostic picture emerges, particularly in oligosymptomatic cases 2.